This article has been updated with additional information from the FDA regarding the scope of the proposed premarket notification exemptions. 

NEW YORK (GenomeWeb) – The US Food and Drug Administration has identified more than 1,000 Class II devices that it plans to exempt from 510(k) premarket notification requirements, including a number of genomic analysis instruments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.